Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

HIFU for Focal Ablation of Prostate Tissue: An Observational Study

NCT: NCT03620786 · RECRUITING

NCT IDNCT03620786
StatusRECRUITING
Start Date2018-09-26
Completion2028-01-31

Brief Summary

The Sonablate HIFU device was approved by the U.S.FDA for prostate tissue ablation in October, 2015. The purpose of this observational research study is to investigate the localized treatment of prostate cancer using HIFU through clinical data and health-related quality of life (HRQOL) questionnaires.

Frequently Asked Questions

What is HIFU for Focal Ablation of Prostate Tissue: An Observational Study?

HIFU for Focal Ablation of Prostate Tissue: An Observational Study is a clinical trial registered under NCT03620786. Current status: RECRUITING.

What is the status of NCT03620786?

The current status of NCT03620786 (HIFU for Focal Ablation of Prostate Tissue: An Observational Study) is: RECRUITING.

When did HIFU for Focal Ablation of Prostate Tissue: An Observational Study start?

HIFU for Focal Ablation of Prostate Tissue: An Observational Study started on 2018-09-26.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑